Wegovy Tablets Vs Injections

If you have been searching for Wegovy tablets, you are not alone — thousands of people across the UK type this exact phrase into Google every single month, hoping to find a convenient pill-form version of the popular weight loss medication. The truth is, Wegovy does not currently come in tablet form, and understanding why can help you make a much more informed decision about your weight loss journey. This guide explains everything you need to know: what Wegovy actually is, how it works, why it is administered as an injection, and what your genuine medically approved alternatives are in the UK right now.

Quick Summary

Wegovy is a prescription-only semaglutide injection approved in the UK for chronic weight management in adults. There is no tablet version available, but this guide covers why that is the case and what your best medically approved alternatives are.

• Wegovy contains semaglutide 2.4mg and is given as a once-weekly subcutaneous injection
• No oral tablet version of Wegovy currently exists — semaglutide degrades rapidly in stomach acid
• Clinical trials show users can lose up to 15% of their body weight over 68 weeks
• Alternatives include Mounjaro (tirzepatide) weight loss injections and Orlos capsules
• A proper medical assessment is required before starting any prescription weight loss treatment in the UK

Table of Contents

1. What is Wegovy and Why Is There No Tablet Form?
2. How Wegovy Works in the Body
3. Who Is Eligible for Wegovy in the UK?
4. Common Side Effects and How to Manage Them
5. Best Wegovy Alternatives Available in the UK in 2026
6. Comparing GLP-1 Weight Loss Treatments Side by Side
7. Key Takeaways
8. When to Seek Professional Advice
9. Scientific References
10. FAQs

What is Wegovy and Why Is There No Tablet Form?

Wegovy is the brand name for semaglutide 2.4mg, a prescription-only injectable medication approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for long-term weight management. It belongs to a class of drugs called GLP-1 receptor agonists, which mimic a naturally occurring gut hormone called glucagon-like peptide-1. When people search for Wegovy tablets, they are generally hoping to avoid the weekly injection routine — which is completely understandable. Needles are not something most of us look forward to, and pill-based medication feels far more familiar.

However, semaglutide as a molecule is a peptide — essentially a small chain of amino acids. When you swallow peptides, your digestive system breaks them down before they ever reach the bloodstream. Stomach acid and digestive enzymes destroy the active compound entirely, rendering it useless. This is the fundamental reason why Wegovy tablets do not exist in the injectable strength used for weight loss. It is not a regulatory or commercial decision — it is basic biochemistry.

That said, Novo Nordisk — the manufacturer of Wegovy — does produce an oral semaglutide tablet called Rybelsus, which is used at much lower doses for type 2 diabetes management. Rybelsus uses a special absorption enhancer (sodium N-(8-[2-hydroxybenzoyl]amino)caprylate, or SNAC) to help the drug survive the stomach environment. However, it is not approved for weight loss in the UK, and the doses are substantially lower than what is needed for the obesity indication. So when patients ask about Wegovy tablets in a weight loss context, the honest answer remains: they do not currently exist in the UK.

• Wegovy is a peptide-based drug that cannot survive oral digestion at therapeutic doses
• Rybelsus is an oral semaglutide tablet but is only approved for type 2 diabetes in the UK
• The MHRA-approved weight loss version of semaglutide requires subcutaneous injection
• Novo Nordisk is researching higher-dose oral semaglutide for obesity, but no UK approval exists yet

How Wegovy Works in the Body

To understand why so many people are searching for Wegovy tablets, it helps to understand what makes this medication so remarkable in the first place. Semaglutide works by activating GLP-1 receptors throughout the body — primarily in the brain, the gut, and the pancreas. The result is a powerful combination of appetite suppression, slower gastric emptying, and improved blood sugar regulation. Many users describe feeling genuinely less hungry for the first time in years, which makes sticking to a calorie deficit far easier than willpower alone can achieve.

In the brain, semaglutide targets the hypothalamus — the region responsible for regulating hunger and satiety. It sends stronger and more frequent signals that you are full, reducing both meal size and the frequency of snacking. In the gut, it slows down how quickly food leaves the stomach, which means you feel fuller for longer after eating. These combined effects are what produce the dramatic weight loss results seen in clinical trials. Wegovy tablets — or rather the injectable form of Wegovy — produced an average weight loss of around 14.9% of body weight in the landmark STEP 1 trial over 68 weeks.

The once-weekly dosing schedule begins at 0.25mg and gradually increases over approximately 16 to 20 weeks to the full maintenance dose of 2.4mg. This gradual escalation is specifically designed to reduce the severity of gastrointestinal side effects, which are the most common reason people discontinue treatment early. The pen device used to administer Wegovy is pre-filled, auto-injecting, and relatively straightforward to use — most people find the actual injection far less daunting than they expected.

• GLP-1 receptor activation reduces appetite and increases feelings of fullness
• Gastric emptying slows, meaning meals satisfy for longer
• Brain signalling changes reduce emotional and habitual eating urges
• Dose escalation over 16–20 weeks minimises early side effects
• Clinical evidence shows up to 15% average body weight reduction at 68 weeks

Who Is Eligible for Wegovy in the UK?

Not everyone who wants to lose weight is eligible for Wegovy in the UK, and it is important to understand the prescribing criteria before you begin your application. Current NICE and NHS guidance (updated in 2026) specifies that Wegovy may be prescribed for adults who have a body mass index (BMI) of 30 kg/m² or above, or a BMI of 27 kg/m² or above alongside at least one weight-related health condition — such as type 2 diabetes, hypertension, sleep apnoea, or dyslipidaemia. Eligibility requires completion of a proper medical assessment, which a qualified prescriber carries out to review your full health history, current medications, and suitability.

There are also a number of contraindications that would prevent someone from receiving a prescription. Wegovy is not suitable for individuals with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, a history of pancreatitis, or severe gastrointestinal disease. Pregnancy and breastfeeding are also exclusion criteria. Women of childbearing potential should use reliable contraception while on treatment, as semaglutide may affect foetal development.

Private prescribing pathways — such as those offered through Cured Pharmacy — allow eligible adults in the UK to access Wegovy without an NHS referral. An online medical assessment is completed, reviewed by a GPhC-registered prescribing pharmacist, and if approved, the medication is dispensed and delivered discreetly to your home. For those looking for non-injectable weight loss support, Orlos (Orlistat) 60mg weight loss capsules offer an oral option that may suit individuals who do not meet the criteria for prescription GLP-1 therapy.

• BMI of 30 or above, or 27 or above with a weight-related health condition
• Must not have a history of medullary thyroid carcinoma or MEN2
• Not suitable during pregnancy or breastfeeding
• A full medical assessment is always required before prescribing
• Private prescribing is available online through regulated UK pharmacies

Common Side Effects and How to Manage Them

One of the most frequent concerns people have — especially those researching Wegovy tablets hoping to avoid the injection — is the side effect profile of semaglutide. The good news is that the majority of side effects are gastrointestinal, manageable, and tend to improve significantly after the initial dose escalation phase. The most commonly reported issues include nausea, vomiting, diarrhoea, constipation, and abdominal discomfort. These symptoms are most pronounced during the early weeks when your body is adjusting to the medication.

Nausea is the single most commonly reported side effect, affecting roughly 44% of participants in clinical trials. However, it is worth noting that the majority of these individuals described the nausea as mild to moderate, and it typically subsided within a few weeks of reaching each new dose. Eating smaller meals, avoiding greasy or heavily spiced food, staying well-hydrated, and not lying down immediately after eating are all practical strategies that help significantly. If nausea becomes severe or persistent, a dose delay or reduction can be discussed with your prescriber.

More serious but rare side effects include pancreatitis, gallbladder disease, and a potential link to thyroid tumours in animal studies — although this thyroid risk has not been confirmed in human trials. Any persistent severe abdominal pain radiating to the back should be investigated immediately as it may indicate pancreatitis. It is also worth being aware of injection site reactions, which are generally mild. People already taking XLS Medical Weight Loss Plus tablets should discuss this with their prescriber before starting semaglutide, to avoid duplication of weight management strategies.

• Nausea affects around 44% of users but is usually mild and time-limited
• Eating smaller, blander meals helps manage early digestive symptoms
• Severe or persistent abdominal pain should be assessed by a doctor urgently
• Injection site reactions are usually minor and resolve quickly
• Side effects typically improve significantly once the maintenance dose is established

Best Wegovy Alternatives Available in the UK in 2026

For people who genuinely cannot tolerate injections, or who do not meet the eligibility criteria for Wegovy, there are several credible alternatives worth exploring. The landscape of weight loss medication in the UK has changed significantly in 2026, with more options available through private prescribing channels than ever before. Understanding each option's mechanism, efficacy, and suitability can help you make the right choice with the support of your prescriber.

Mounjaro (tirzepatide) has emerged as a particularly exciting alternative. Unlike Wegovy, which activates only the GLP-1 receptor, Mounjaro acts on both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. This dual mechanism has produced even more impressive weight loss results in trials — an average of up to 22.5% body weight reduction at the highest dose in the SURMOUNT-1 trial. It is also administered as a weekly injection using a simple KwikPen device. You can explore Mounjaro weight loss injections (tirzepatide) KwikPen if you are looking for a highly effective injectable alternative.

For those seeking an entirely non-injectable oral option, Orlos (Orlistat) 60mg is available without a prescription for adults with a BMI of 28 or above. Orlistat works by blocking approximately a third of the fat you eat from being absorbed by the body. It is less potent than GLP-1 medications and requires strict adherence to a low-fat diet, but it remains a clinically validated oral weight loss aid. Similarly, XLS Medical Direct Fat Binder sachets offer a non-prescription approach using a plant-based fibre complex that binds dietary fats before they are absorbed.

• Mounjaro (tirzepatide) targets both GLP-1 and GIP receptors for superior weight loss results
• Orlos (Orlistat) is an oral capsule option available over the counter for eligible adults
• XLS Medical Fat Binder is a non-prescription sachet supplement for added support
• Lifestyle interventions — diet, exercise, and behavioural therapy — remain foundational to all treatments
• A medical assessment helps identify the most appropriate option for your individual health profile

Comparing GLP-1 Weight Loss Treatments Side by Side

With multiple treatments now available in the UK, it can feel overwhelming trying to work out which one is right for you. The table below provides a clear, side-by-side comparison of the main prescription and over-the-counter weight loss options, including the Wegovy tablets question addressed directly alongside its injectable counterpart. This should help you go into your medical consultation feeling far more informed and confident about the conversation.

Treatment	Active Ingredient	Administration	Average Weight Loss	Prescription Required	UK Approved for Weight Loss
Wegovy	Semaglutide 2.4mg	Weekly injection	~15% body weight	Yes	Yes (MHRA)
Mounjaro	Tirzepatide 5–15mg	Weekly injection	Up to ~22.5%	Yes	Yes (MHRA, 2023)
Saxenda	Liraglutide 3mg	Daily injection	~5–8% body weight	Yes	Yes (MHRA)
Orlos (Orlistat)	Orlistat 60mg	Oral capsule (3x daily)	~5% body weight	No (OTC)	Yes
XLS Medical Fat Binder	Litramine (plant fibre)	Oral sachet	Variable	No (OTC)	As a medical device
Wegovy tablets (oral)	N/A	Does not exist	N/A	N/A	No

As the table illustrates, the question of Wegovy tablets is definitively answered — no such product exists or is approved for weight loss in the UK. However, the range of alternatives is genuinely impressive. The injectable options (Wegovy and Mounjaro especially) offer the most significant clinical weight loss results, while oral options like Orlistat remain valuable for those who are not eligible for or do not want injection-based treatment. If you are managing any underlying metabolic conditions, such as thyroid concerns, it is worth having a thyroid function test before commencing any weight loss medication, as thyroid disorders can significantly impact metabolism and treatment response.

Your prescriber will weigh up your BMI, health history, other medications, and personal preferences to recommend the most appropriate treatment. The key point is that real, clinically validated help is available — and it does not require a tablet form of Wegovy to be effective. Whether you start with an injectable GLP-1 agonist or a non-prescription fat binder, the most important step is simply to begin with proper medical support rather than attempting unregulated or unproven alternatives found online.

• Mounjaro currently offers the highest average weight loss of any approved UK treatment
• Wegovy remains highly effective and more widely established in NHS and private prescribing
• Orlistat is the go-to oral option for those not eligible for prescription injectables
• Always check for thyroid conditions and other metabolic factors before starting treatment
• Unsupervised or unregulated weight loss products should be avoided in favour of MHRA-approved options

Key Takeaways

• Wegovy tablets do not exist — Wegovy is only available as a once-weekly subcutaneous injection containing semaglutide 2.4mg
• The peptide structure of semaglutide means it cannot be swallowed in therapeutic doses, as stomach acid destroys the molecule
• Effective prescription alternatives such as Mounjaro (tirzepatide) and non-prescription options such as Orlistat are readily available in the UK in 2026
• Eligibility for prescription GLP-1 treatments requires a BMI of 30 or above, or 27 or above with a weight-related condition, assessed by a qualified prescriber
• Private online prescribing through regulated UK pharmacies like Cured Pharmacy offers a convenient, medically safe pathway to access weight loss treatment

When to Seek Professional Advice

Weight loss medication — whether injectable or oral — is not something you should navigate alone. You should seek professional medical advice before starting any treatment, but there are also specific situations where speaking to a prescriber or doctor urgently is essential. If you experience severe nausea, persistent vomiting, acute abdominal pain (particularly pain that radiates to your back), a rapid or irregular heartbeat, or sudden vision changes while on any GLP-1 medication, seek medical attention immediately as these can indicate serious complications including pancreatitis or gallbladder problems.

You should also speak to a prescriber if you are currently taking medications for type 2 diabetes, blood pressure, or depression, as some of these interact with semaglutide or tirzepatide. Women who become pregnant during treatment must stop immediately and inform their GP. If you are unsure whether you are eligible for prescription weight loss treatment, an online consultation with Cured Pharmacy's GPhC-registered prescribing pharmacists takes under three minutes and provides personalised, expert guidance.

• Seek urgent help for severe abdominal pain, persistent vomiting, or signs of pancreatitis
• Tell your prescriber about all medications before starting any weight loss injection
• Stop treatment immediately and see a doctor if you become pregnant
• Consult a prescriber if you notice unexplained mood changes, heart palpitations, or allergic reactions

Frequently Asked Questions

How long does it take for Wegovy to start working?

Wegovy typically begins to show noticeable weight loss results within the first four to eight weeks of treatment. Most clinical trial participants achieved significant weight reduction — often over 10% of body weight — after 68 weeks of consistent weekly injections at the full maintenance dose of 2.4mg semaglutide.

Is Wegovy safe to use long term?

Wegovy is considered safe for long-term use when prescribed and monitored by a qualified healthcare professional. Clinical data reviewed up to 2026 supports its use over extended periods, though common side effects such as nausea and digestive discomfort may occur, particularly during the dose escalation phase.

Can you take Wegovy with other weight loss medications?

Wegovy should not be combined with other GLP-1 receptor agonists or weight loss injections such as Ozempic, Saxenda, or Mounjaro. Combining these medications significantly increases the risk of serious side effects. Always inform your prescribing pharmacist or doctor about all medications and supplements you are currently taking.

What is the starting dose of Wegovy?

The starting dose of Wegovy is 0.25mg semaglutide once weekly for the first four weeks, which helps your body adjust and reduces early side effects. The dose is then gradually increased every four weeks, ultimately reaching the full maintenance dose of 2.4mg once weekly after approximately 16 to 20 weeks of treatment.

Scientific References

1. NICE Technology Appraisal TA875 — Semaglutide for managing overweight and obesity (2023). National Institute for Health and Care Excellence.
2. MHRA Regulatory Approval of Wegovy (Semaglutide). Medicines and Healthcare products Regulatory Agency, UK Government.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 Trial). New England Journal of Medicine, 2021; 384:989–1002.

Note: The oral semaglutide tablet (Wegovy tablets in pill form) does not currently exist as an MHRA-approved weight loss product. Always rely on information from regulated UK sources including NICE, the MHRA, and GPhC-registered prescribers when making decisions about weight loss treatment.